布地奈德联合脾氨肽治疗喘息性支气管炎患儿的临床疗效

doi:10.3969/j.issn.1671-7171.2025.10.016

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1208 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the clinical efficacy of budesonide combined with spleen aminopeptide in the treatment of children with asthmatic bronchitis. 【Methods】A total of 80 children with asthmatic bronchitis admitted to our hospital from January 2020 to May 2022 were selected and grouped by the ball-touching method. Those with odd numbers were assigned to the control group (n=40), and those with even numbers to the observation group (n=40). The control group was given conventional treatment combined with budesonide atomization inhalation, while the observation group was given additional spleen aminopeptide treatment on the basis of the control group. The clinical efficacy, pulmonary function indexes [forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), maximum voluntary ventilation (MVV)] before and after treatment, immune function indexes (CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺), and serum inflammatory factor [interleukin-4 (IL-4), interleukin-8 (IL-8), tumor necrosis factor (TNF-α), monocyte chemoattractant protein-1 (MCP-1)] levels were compared between the two groups. 【Results】After treatment, the total effective rate of the observation group was higher than that of the control group (P<0.05); the levels of FEV₁, FVC, MVV, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in the observation group were higher than those in the control group (P<0.05), while CD8⁺ was lower than that in the control group (P<0.05); the levels of IL-4, IL-8, TNF-α, and MCP-1 in the observation group were lower than those in the control group (P<0.05).【Conclusion】Budesonide combined with spleen aminopeptide in the treatment of children with asthmatic bronchitis can significantly improve the clinical therapeutic effect, enhance pulmonary function and immune function, and reduce the levels of serum inflammatory factors.

Key words： Bronchitis Budesonide Biological Factors Child Treatment Outcome

Received: 24 December 2024

PACS:

R562.21

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Qingliang
	CHEN Xuan
	CHEN Qi

Cite this article:

XU Qingliang,CHEN Xuan,CHEN Qi. Clinical Efficacy of Budesonide Combined with Spleen Aminopeptide in the Treatment of Children with Asthmatic Bronchitis[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(10): 1736-1738.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.10.016 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I10/1736

[1] 梁洪富,李萍,周燕子. 肺力咳合剂联合布地奈德对喘息性支气管炎患儿症状缓解时间及炎症反应的影响[J].现代诊断与治疗,2024,35(2):180-182.
[2] 刘海燕,陈华芳,李建军. 氨溴索联合布地奈德治疗对小儿喘息性支气管炎临床疗效、炎性因子及免疫功能的影响[J].实用医院临床杂志,2021,18(3):135-138.
[3] 冯勤蕙,魏亮,胡检生. 布地奈德联合特布他林雾化吸入治疗对喘息性支气管炎患儿炎性反应及免疫功能的影响[J].临床合理用药杂志,2022,15(30):98-100.
[4] 张春利. 脾氨肽联合沙美特罗替卡松治疗小儿支气管哮喘的临床观察[J].临床研究,2022,30(8):63-66.
[5] 胡亚美, 江载芳. 诸福棠实用儿科学[M]. 7版.北京:人民卫生出版社, 2008: 1171-1174.
[6] 陈研,周海霞,丁婷. 桑杏苈黄汤在痰热闭肺证急性喘息性支气管炎患儿治疗中的应用[J].辽宁中医杂志,2024,51(6):96-99.
[7] 叶惠,王婷,陈思航. 孟鲁司特钠对儿童喘息性支气管炎临床疗效及免疫功能的影响[J].贵州医药,2023,47(3):380-381.
[8] 连换杰,刘玉娇,邓娅君. 重组人干扰素α2b联合甲强龙对喘息性支气管炎患儿EOS、SP-D、25-(OH)D₃水平的影响[J].国际检验医学杂志,2022,43(12):1444-1447.
[9] 热孜亚·玉苏甫,努尔艾力·塞买提. 单磷酸阿糖腺苷联合布地奈德对毛细支气管炎患儿血清MCP-1、INF-γ水平的影响与安全性分析[J].现代医学与健康研究(电子版),2021,5(8):51-53.
[10] 田卫东,熊秀. 苏沈九宝汤联合布地奈德雾化吸入对喘息性支气管炎患儿症状及肺功能的影响[J].湖北中医药大学学报,2021,23(6):68-70.
[11] 王宁,刘艳. 布地奈德联合β受体激动剂对儿童喘息性支气管炎气道重塑的影响[J].海南医学,2021,32(24):3217-3220.
[12] 唐安,巫小燕. 脾氨肽口服冻干粉结合布地奈德对小儿支气管肺炎临床疗效及免疫功能的影响[J].医学理论与实践,2020,33(20):3436-3437.
[13] 张婵,吕继忠. 脾氨肽联合布地奈德雾化吸入治疗小儿支气管哮喘的效果及对免疫功能、炎性细胞因子的影响[J].齐齐哈尔医学院学报,2020,41(16):2009-2011.
[14] 贺文奇,王鹏,刘兴政,等. 脾氨肽辅助纤维支气管镜肺泡灌洗对肺炎支原体肺炎患者免疫功能及血清炎症因子的影响[J].中国药物经济学,2023,18(8):93-96.